Ifosfamide
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01181 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | female breast carcinoma | KG + DL |
| 2 | unclassified myelodysplastic syndrome | KG + DL |
| 3 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 4 | refractory cytopenia of childhood | KG + DL |
| 5 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 6 | aregenerative anemia | KG + DL |
| 7 | rhabdomyosarcoma (disease) | KG + DL |
| 8 | myelodysplastic syndrome | KG + DL |
| 9 | monocytic leukemia | KG + DL |
| 10 | botryoid-type embryonal rhabdomyosarcoma of the vagina | KG + DL |
| 11 | parameningeal embryonal rhabdomyosarcoma | KG + DL |
| 12 | extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 13 | embryonal extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 14 | prostate embryonal rhabdomyosarcoma | KG + DL |
| 15 | liver sarcoma | KG + DL |
| 16 | sickle cell-beta-thalassemia disease syndrome | KG + DL |
| 17 | hereditary persistence of fetal hemoglobin-sickle cell disease syndrome | KG + DL |
| 18 | sickle cell-hemoglobin E disease syndrome | KG + DL |
| 19 | sickle cell-hemoglobin c disease syndrome | KG + DL |
| 20 | sickle cell-hemoglobin d disease syndrome | KG + DL |
| 21 | small cell lung carcinoma | KG + DL |
| 22 | neuroblastoma | KG + DL |
| 23 | primary pulmonary lymphoma | KG + DL |
| 24 | pulmonary blastoma | KG + DL |
| 25 | well-differentiated fetal adenocarcinoma of the lung | KG + DL |
| 26 | nipple carcinoma | KG + DL |
| 27 | ganglioneuroblastoma (disease) | KG + DL |
| 28 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 29 | retroperitoneal neoplasm | KG + DL |
| 30 | estrogen-receptor negative breast cancer | KG + DL |
| 31 | hormone-resistant breast carcinoma | KG + DL |
| 32 | estrogen-receptor positive breast cancer | KG + DL |
| 33 | Ehrlich tumor carcinoma | KG + DL |
| 34 | breast carcinoma by gene expression profile | KG + DL |
| 35 | bilateral breast carcinoma | KG + DL |
| 36 | uterine corpus sarcoma | KG + DL |
| 37 | Ewing sarcoma | KG + DL |
| 38 | dermatofibrosarcoma protuberans | KG + DL |
| 39 | primary non-gestational choriocarcinoma of ovary | KG + DL |
| 40 | rheumatoid arthritis | KG + DL |
| 41 | hereditary breast ovarian cancer syndrome | KG + DL |
| 42 | myelomonocytic leukemia | KG + DL |
| 43 | mixed endometrial stromal and smooth muscle tumor | KG + DL |
| 44 | pancreatic adenocarcinoma | KG + DL |
| 45 | brachydactyly-syndactyly syndrome | KG + DL |
| 46 | myeloid leukemia | KG + DL |
| 47 | liposarcoma | KG + DL |
| 48 | lissencephaly spectrum disorders | KG + DL |
| 49 | leukemia (disease) | KG + DL |
| 50 | vestibular neuronitis | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.